COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,436 Articles (22,835 medRxiv, 8,601 bioRxiv)

Most recent first Previous |  Page 967: Articles 9661-9670  | Next

Efficacy and safety of nitazoxanide combined with ritonavir-boosted atazanavir for the treatment of mild to moderate COVID-19
Fowotade, A., Bamidele, F., Egbetola, B., Adefuye, B. O., Fagbamigbe, A. F., Adeagbo, B. A., Olagunoye, A., Ojo, T. O., Adebiyi, A. O., Olagunju, O. I., Ladipo, O. T., Akinloye, A., Onayade, A., Bolaji, O. O., Happi, C., Rannard, S., Owen, A., Olagunju, A.
10.1101/2022.02.03.22270152 — Posted: 2022-02-04
OraSure InteliSwab Rapid Antigen Test performance with the SARS-CoV-2 Variants of Concern Alpha, Beta, Gamma, Delta, and Omicron
Weishampel, Z., Young, J., Fischl, M., Fischer, R., Owusu, I. O., Riopelle, J., Schulz, J., Port, J. R., Saturday, T., van Doremalen, N., Berry, J., Munster, V., Yinda, C. K.
10.1101/2022.02.02.22270254 — Posted: 2022-02-04
Equitable COVID-19 vaccine prioritization: front-line workers or 65-74 year olds?
Rumpler, E., Feldman, J. M., Bassett, M. T., Lipsitch, M.
10.1101/2022.02.03.22270414 — Posted: 2022-02-04
Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities: surveillance results from southern Sweden
Kahn, F., Bonander, C., Moghaddassi, M., Rasmussen, M., Malmqvist, U., Inghammar, M., Bjork, J.
10.1101/2022.02.03.22270389 — Posted: 2022-02-04 Discussion: Onsite
Effectiveness of the inactivated COVID-19 vaccine (CoronaVac) in adult population in Indonesia
Suryatma, A., Anasi, R., Hananto, M., Hermawan, A., Ramadhany, R., Indalao, I. L., Agustiningsih, A., Fikriyah, E. H., Tejayanti, T., Rustika, R., Tobing, K. L., Suarjaya, K., Widia, I. W., Dhewantara, P. W.
10.1101/2022.02.02.22270351 — Posted: 2022-02-04
Modeling Vaccinations, Virus Variants and Lockdown: Early guidance for Sars-Cov-2 health policies in India
Zhang, Y., Kapoor, S.
10.1101/2022.02.02.22270353 — Posted: 2022-02-04
Fatality assessment and variant risk monitoring for COVID-19 using three new hospital occupancy related metrics
Zhang, P.-W., Zhang, S. H., Li, W.-F., Keuthan, C. J., Li, S., Takaesu, F., Berlinicke, C. A., Wan, J., Sun, J., Zack, D. J.
10.1101/2022.02.03.22270417 — Posted: 2022-02-04
RISK STRATIFICATION OF PATIENTS WITH COVID-19 DISEASE THROUGH THE USE OF CLINICAL SCORES IN AN EMERGENCY DEPARTMENT. A review of the literature
Zanella, S., Zanella, F., Mancosu, A., Brugnolli, A., Carrara, A., Bevilacqua, A., Marinelli, E., Ricci, N.
10.1101/2022.02.03.22270401 — Posted: 2022-02-04
Antibody affinity and concentration of convalescent sera provide context for reduced SARS-CoV-2 Omicron spike affinity of therapeutic antibodies
Fiedler, S., Devenish, S. R. A., Morgunov, A. S., Ilsley, A., Ricci, F., Emmenegger, M., Kosmoliaptsis, V., Theel, E. S., Mills, J. R., Sholukh, A. M., Aguzzi, A. A. A., Iwasaki, A., Lynn, A. K., Knowles, T. P. J.
10.1101/2022.02.03.478946 — Posted: 2022-02-04
SurvMaximin: Robust Federated Approach to Transporting Survival Risk Prediction Models
Wang, X., Zhang, H. G., Xiong, X., Hong, C., Weber, G. M., Brat, G. A., Bonzel, C.-L., Luo, Y., Duan, R., Palmer, N. P., Hutch, M. R., Gutierrez-Sacristan, A., Bellazzi, R., Chiovato, L., Cho, K., Dagliati, A., Estiri, H., Garcia-Barrio, N., Griffier, R., Hanauer, D. A., Ho, Y.-L., Holmes, J. H., Keller, M. S., Klann, J. G., L'Yi, S., Lozano-Zahonero, S., Maidlow, S. E., Makoudjou, A., Malovini, A., Moal, B., Moore, J. H., Morris, M., Mowery, D. L., Murphy, S. N., Neuraz, A., Ngiam, K. Y., Omenn, G. S., Patel, L. P., Pedrera-Jimenez, M., Prunotto, A., Samayamuthu, M. J., Sanz Vidorreta, F. J., Schriver, E. R., Schubert, P., Serrano-Balazote, P., South, A. M., Tan, A. L., Tan, B. W. L., Tibollo, V., Tippmann, P., Visweswaran, S., Xia, Z., Yuan, W., Zöller, D., Kohane, I. S., The Consortium for Clinical Characterization of COVID-19 by EHR (4CE), , Avillach, P., Guo, Z., Cai, T.
10.1101/2022.02.03.22270410 — Posted: 2022-02-04

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).